Breast cancer management: opportunities and barriers to an individualized approach.

Edith A. Perez

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

A personalized approach to breast cancer management is increasingly possible with state of the art diagnostics and treatments. However, many challenges still exist in choosing the right therapeutic strategy and the right dosing for a specific patient population. Biomarkers such as estrogen receptor, progesterone receptor, and HER-2 status are used to tailor therapy, but success rates with targeted therapy suggest that appropriate patient populations still require greater definition. The introduction of the genomic era has likewise advanced the ability to offer a tailored approach to breast cancer management, but much work is still needed in this area as well. Microarray-based gene expression profiles have demonstrated initial promise, but we need a better understanding of more complex tumor signaling pathways. Strategies include annotated tumor specimens, next-generation gene sequencing, proteomics, and metabolomics. An individualized approach to breast cancer management has the potential to offer clear clinical benefits and the ability to bring more tailored, cost-effective strategies to the market. The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion.

Original languageEnglish (US)
Pages (from-to)20-22
Number of pages3
JournalThe oncologist
Volume16 Suppl 1
DOIs
StatePublished - 2011

Fingerprint

Breast Neoplasms
Metabolomics
Progesterone Receptors
Therapeutics
Transcriptome
Estrogen Receptors
Proteomics
Population
Neoplasms
Biomarkers
Costs and Cost Analysis
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Breast cancer management : opportunities and barriers to an individualized approach. / Perez, Edith A.

In: The oncologist, Vol. 16 Suppl 1, 2011, p. 20-22.

Research output: Contribution to journalArticle

@article{c12b0a3df5f14cdf9fdbfa96a0d5053f,
title = "Breast cancer management: opportunities and barriers to an individualized approach.",
abstract = "A personalized approach to breast cancer management is increasingly possible with state of the art diagnostics and treatments. However, many challenges still exist in choosing the right therapeutic strategy and the right dosing for a specific patient population. Biomarkers such as estrogen receptor, progesterone receptor, and HER-2 status are used to tailor therapy, but success rates with targeted therapy suggest that appropriate patient populations still require greater definition. The introduction of the genomic era has likewise advanced the ability to offer a tailored approach to breast cancer management, but much work is still needed in this area as well. Microarray-based gene expression profiles have demonstrated initial promise, but we need a better understanding of more complex tumor signaling pathways. Strategies include annotated tumor specimens, next-generation gene sequencing, proteomics, and metabolomics. An individualized approach to breast cancer management has the potential to offer clear clinical benefits and the ability to bring more tailored, cost-effective strategies to the market. The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion.",
author = "Perez, {Edith A.}",
year = "2011",
doi = "10.1634/theoncologist.2011-S1-20",
language = "English (US)",
volume = "16 Suppl 1",
pages = "20--22",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",

}

TY - JOUR

T1 - Breast cancer management

T2 - opportunities and barriers to an individualized approach.

AU - Perez, Edith A.

PY - 2011

Y1 - 2011

N2 - A personalized approach to breast cancer management is increasingly possible with state of the art diagnostics and treatments. However, many challenges still exist in choosing the right therapeutic strategy and the right dosing for a specific patient population. Biomarkers such as estrogen receptor, progesterone receptor, and HER-2 status are used to tailor therapy, but success rates with targeted therapy suggest that appropriate patient populations still require greater definition. The introduction of the genomic era has likewise advanced the ability to offer a tailored approach to breast cancer management, but much work is still needed in this area as well. Microarray-based gene expression profiles have demonstrated initial promise, but we need a better understanding of more complex tumor signaling pathways. Strategies include annotated tumor specimens, next-generation gene sequencing, proteomics, and metabolomics. An individualized approach to breast cancer management has the potential to offer clear clinical benefits and the ability to bring more tailored, cost-effective strategies to the market. The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion.

AB - A personalized approach to breast cancer management is increasingly possible with state of the art diagnostics and treatments. However, many challenges still exist in choosing the right therapeutic strategy and the right dosing for a specific patient population. Biomarkers such as estrogen receptor, progesterone receptor, and HER-2 status are used to tailor therapy, but success rates with targeted therapy suggest that appropriate patient populations still require greater definition. The introduction of the genomic era has likewise advanced the ability to offer a tailored approach to breast cancer management, but much work is still needed in this area as well. Microarray-based gene expression profiles have demonstrated initial promise, but we need a better understanding of more complex tumor signaling pathways. Strategies include annotated tumor specimens, next-generation gene sequencing, proteomics, and metabolomics. An individualized approach to breast cancer management has the potential to offer clear clinical benefits and the ability to bring more tailored, cost-effective strategies to the market. The current issues facing the delivery of individualized breast cancer care will be the focus of this discussion.

UR - http://www.scopus.com/inward/record.url?scp=79959518092&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959518092&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2011-S1-20

DO - 10.1634/theoncologist.2011-S1-20

M3 - Article

C2 - 21278437

AN - SCOPUS:79959518092

VL - 16 Suppl 1

SP - 20

EP - 22

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -